Download Booklet - Diabetes in Asia Study Group

Abstract Title
What does the evidence say about the fetal and neonatal safety about the use of oral Ant
Diabetic Drugs (aDD) in pregnancy and Lactation
author : Dr. shabeen naz Masood ;Muhammad faraz Masood MD
objective : to review the safety of oral anti diabetic agents in pregnancy and Lactation
Results :
•
•
•
•
•
•
•
•
Glyburide and metformin are not teratogenic in humans when used in clinically
recommended doses.
Glyburide may be used for treatment of gestational diabetes in some women.
Metformin may be used safely for ovulation in women with pCos.
Metformin reduces the development of GDM, was not teratogenic and did not affect
birth length, weight, growth motor or social development in children in first 18 months
of life
tolbutamide, Chloropropamide cross into the breast milk
None of the glyburides pass in the breast milk samples.
MetforMin: excreted in the breast milk at very low levels
no differences in weight, height or motor-social development of the newborn or in the
infants up to 3-6 months of age are reported.
CONCLUSIONS:.
•
•
•
•
•
there is evidence that certain oral hypoglycemic drugs might be safe in pregnancy, or
at least, are significantly less dangerous to the developing fetus than poorly controlled
diabetes.
Metformin, Glyburide and Glypizide are compatible with breast feeding
these agents may be used in research settings
if the patient needs intervention but refuses insulin therapy,
patient is aware of potential or probable risks
52